Biomarkers in Gastrointestinal Cancer: Evidence-Based Treatment in the Precision Medicine Era

Biomarkers in Gastrointestinal Cancer: Evidence-Based Treatment in the Precision Medicine Era

Friday, January 21, 2022 in San Francisco, California
Dinner -- San Francisco Marriott Marquis, 6:00 PM PT
Yerba Buena Ballroom Salons 1-6

Agenda

Join us for this CME-certified symposium held in conjunction with the 2022 Gastrointestinal Cancers Symposium featuring expert perspectives on molecular testing, predictive biomarkers, and targeted therapy for patients with GI malignancies. Bring your questions and case challenges for the live Q&A session with the expert panel faculty at the end of the session.

Not an official event of the 2022 Gastrointestinal Cancers Symposium. Not sponsored, endorsed, or accredited by ASCO or the Conquer Cancer Foundation.

In accordance with San Francisco’s local regulations, you must show proof of vaccination* in order to go into an event serving food or drinks indoors. For more information on San Francisco’s vaccination requirements, please visit: https://sf.gov/information/vaccine-required.

*If you do not have your vaccination record card, find out other ways to verify you have been vaccinated.

Additionally, all in-person attendees are required to wear medical-grade masks while attending the symposium, in line with the existing San Francisco mask mandate for all public buildings, regardless of vaccination status. For more information regarding San Francisco’s mask mandate, please visit: https://sf.gov/information/wear-mask.

For more information regarding ASCO Gastrointestinal Cancers Symposium Health & Safety, we encourage you to visit: https://conferences.asco.org/gi/health-safety.

Clinical Care Options is committed to providing a safe and healthy environment for all our participants. Our decisions and preventive measures are guided by the requirements and recommendations of the CDC alongside federal, state, and local health authorities. We work with each program venue to implement preventive measures to reduce the potential spread of COVID-19. Therefore, all attendees will be asked to present their ASCO GI conference badge -OR- proof of vaccination AND Government issued ID, in order to gain admittance to the Current and Emerging Systemic Therapies for Hepatocellular Carcinoma: Clinical Evidence and Guideline Recommendations symposium.

  • Histology-Agnostic Biomarkers in GI Malignancies
  • Biomarker-Driven Treatment of Advanced Colorectal Cancer
  • Biomarker-Driven Treatment of Pancreatic and Hepatobiliary Cancer
  • Biomarker-Driven Treatment: Gastric, Esophageal, and Gastroesophageal Junction Cancers
  • Live Audience Question and Answer Session

Faculty

Program Director
John L. Marshall, MD

Chief, Division of Hematology/Oncology
Department of Medicine
Georgetown University Hospital
Washington, DC

Faculty
Manish A. Shah, MD

Bartlett Family Professor of Gastrointestinal Oncology
Chief, 
Solid Tumor Services
Director, Gastrointestinal Oncology Program
Co-Director, Center for Advanced Digestive Care
Weill Cornell Medical College
NewYork-Presbyterian Hospital
New York, New York

Faculty
Rachna Shroff, MD

Assistant Professor of Medicine
Chief
, Section of GI Medical Oncology
Director, UACC Clinical Trials Office
The University of Arizona Cancer Center
Tucson, Arizona

Goal Statement

The goal of this program is to improve the knowledge and competence of learners in biomarker testing to guide selection of individualized treatments for patients with gastrointestinal malignancies.

Target Audience

This educational program is intended for medical oncologists, and other healthcare professional who treat patients with gastrointestinal cancers.

Learning Objectives

  • Apply the available data and expert recommendations to order and accurately interpret molecular profiling for patients with GI malignancies to guide treatment selection
  • Plan therapeutic strategies for patients with GI malignancies based on predictive biomarker assessment
  • Counsel patients about how the molecular profile will guide therapy decisions and potential need for additional biopsy
  • Appraise ongoing clinical trials for novel biomarker-driven treatment strategies in GI malignancies for patient counsel and potential enrollment

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.